Vertex Pharmaceuticals (VRTX) Financial Analysis & Valuation | Quarter Chart
Vertex Pharmaceuticals (VRTX)
VRTXPrice: $499.65
Fair Value: 🔒
🔒score
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis trans... more
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializ... more
Description
Shares
| Market Cap | $126.81B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Reshma Kewalramani |
| IPO Date | 1991-07-24 | CAGR | 0.28% |
| Employees | 6,100 | Website | www.vrtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.51% | Total Yield | 0.51% |
VRTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $126.49B | P/E Ratio | 26.55 |
| Forward P/E | 23.27 | PEG Ratio | 0.48 |
| P/S Ratio | 30.87 | P/B Ratio | 19.55 |
| P/CF Ratio | 89.13 | P/FCF Ratio | 101.81 |
| EPS | $18.82 | EPS Growth 1Y | — |
| EPS Growth 3Y | 34.24% | EPS Growth 5Y | 60.57% |
| Revenue Growth 1Y | 10.41% | Gross Margin | 0.86% |
| Operating Margin | 0.39% | Profit Margin | 0.35% |
| ROE | 0.24% | ROA | 0.16% |
| ROCE | 0.21% | Current Ratio | 3.02 |
| Quick Ratio | 2.57 | Cash Ratio | 1.42 |
| Debt/Equity | 0.1 | Interest Coverage | 463.67 |
| Altman Z Score | 12.9 | Piotroski Score | 5 |